The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
Study Type
OBSERVATIONAL
Enrollment
500
According to the product label
Local Institution - 0003
Singapore, Singapore
Local Institution - 002
Seoul, Seoul Teugbyeolsi, South Korea
Local Institution - 0001
Taipei, Taiwan
Participant age
Time frame: Baseline
Participant sex
Time frame: Baseline
Participant race
Time frame: Baseline
Participant weight
Time frame: Baseline
Participant height
Time frame: Baseline
Participant body mass index (BMI)
Time frame: Baseline
Participant smoking status
Time frame: Baseline
Participant drinking status
Time frame: Baseline
Family history of MDS or other hematopoietic cancers
Time frame: Baseline
Participant myelodysplastic syndromes diagnosis information
Time frame: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis
Time frame: Baseline
Participant comorbidities at diagnosis
Time frame: Baseline
Participant Charlson comorbidity index (CCI) score at diagnosis
Time frame: Baseline
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Prior clinical diagnosis of other cancers
Time frame: Baseline
Prior clinical diagnosis of hematological diseases
Time frame: Baseline
Anemia status at diagnosis
Time frame: Bseline
Thrombocytopenia status at diagnosis
Time frame: Baseline
Neutropenia status at diagnosis
Time frame: Baseline
Iron overload status at diagnosis
Time frame: Baseline
Red blood cell (RBC) transfusion dependence status at diagnosis
Time frame: Baseline
International Prognostic Scoring System (IPSS) score at diagnosis
Time frame: Baseline
Revised International Prognostic Scoring System (IPSS-R) score at diagnosis
Time frame: Baseline
Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis
Time frame: Baseline
Bone marrow aspirate results
Time frame: Baseline and up to 2-years
Presence of dysplasia
Time frame: Baseline and up to 2-years
Cytogenetic test results
Time frame: Baseline and up to 2-years
Mutation test results at diagnosis
Time frame: Baseline
Complete blood count test results at diagnosis
Time frame: Baseline
Mean corpuscular volume (MCV)
Time frame: Baseline and up to 2-years
C-reactive protein (CRP)
Time frame: Baseline and up to 2-years
Serum ferritin (SF) level
Time frame: Baseline and up to 2-years
Serum erythropoietin levels
Time frame: Baseline and up to 2-years
Lactate dehydrogenase (LDH)
Time frame: Baseline and up to 2-years
Initial treatment received following diagnosis
Time frame: Baseline
Prior treatments and concomitant medications received
Time frame: Baseline
Subsequent treatments received
Time frame: Up to 2-years
Time from diagnosis to treatment initiation
Time frame: Baseline
Treatment duration
Time frame: Up to 2-years
Real-world overall survival (rwOS)
Time frame: Baseline and up to 2-years
Time to disease-risk progression (per IPSS-R)
Time frame: Baseline and up to 2-years
Time to acute myeloid leukemia (AML) progression
Time frame: Baseline and up to 2-years
Time to iron overload
Time frame: Baseline and up to 2-years
Overall response rate (ORR)
Time frame: Baseline and up to 2-years
Duration of response (DOR)
Time frame: Baseline and up to 2-years
Real-world relapse-free survival (rwRFS)
Time frame: Baseline and up to 2-years